Similarly, Iinuma et al. demonstrated that the combination of CEA, cytokeratin, and CD133 was a reliable prognostic marker for poor outcomes in Dukes’ stage B and C CRC cases [3]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.